Ser538

Site Information
EKLKGKGsPRPQAPK SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 470937
Available spectra: 1 CST

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 14 , 15 , 16 , 17 , 18 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 )
Disease tissue studied:	breast cancer ( 4 , 7 , 8 , 16 ) , breast ductal carcinoma ( 7 ) , HER2 positive breast cancer ( 2 ) , luminal A breast cancer ( 2 ) , luminal B breast cancer ( 2 ) , breast cancer, surrounding tissue ( 2 ) , breast cancer, triple negative ( 2 , 7 ) , cervical cancer ( 35 ) , cervical adenocarcinoma ( 35 ) , colorectal cancer ( 21 , 22 ) , colorectal carcinoma ( 21 , 22 ) , gastric cancer ( 24 , 25 ) , gastric carcinoma ( 24 , 25 ) , leukemia ( 17 , 20 ) , acute myelogenous leukemia ( 17 , 20 ) , acute erythroid leukemias, including erythroleukemia (M6a) and very rare pure erythroid leukemia (M6b) ( 15 ) , acute megakaryoblastic leukemia (M7) ( 15 ) , acute monoblastic leukemia (M5a) or acute monocytic leukemia (M5b) ( 15 ) , acute myeloblastic leukemia, with granulocytic maturation (M2) ( 15 ) , acute myeloblastic leukemia, without maturation (M1) ( 15 ) , lung cancer ( 10 , 16 , 31 ) , non-small cell lung cancer ( 10 , 16 ) , non-small cell lung adenocarcinoma ( 10 ) , B cell lymphoma ( 15 ) , non-Hodgkin's lymphoma ( 15 ) , ovarian cancer ( 7 ) , multiple myeloma ( 15 )
Relevant cell line - cell type - tissue:	293 (epithelial) [AT1 (human), transfection, AT1R stable transfected HEK293] ( 34 ) , A549 (pulmonary) ( 11 ) , AML-193 (monocyte) ( 15 ) , breast ( 2 , 7 ) , BT-549 (breast cell) ( 16 ) , Calu-3 (pulmonary) ( 10 ) , CL1-0 (pulmonary) ( 31 ) , CL1-1 (pulmonary) ( 31 ) , CL1-2 (pulmonary) ( 31 ) , CL1-5 (pulmonary) ( 31 ) , CMK (megakaryoblast) ( 15 ) , CTS (myeloid) ( 15 ) , DOHH2 ('B lymphocyte, precursor') ( 15 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 18 ) , Flp-In T-Rex-293 (epithelial) ( 18 ) , H2077 (pulmonary) ( 16 ) , H322M (pulmonary) ( 16 ) , HCC1937 (breast cell) ( 16 ) , HCC2279 (pulmonary) ( 16 ) , HCC827 (pulmonary) ( 10 ) , HCT116 (intestinal) ( 21 , 22 ) , HEK293T (epithelial) ( 5 , 40 ) , HEL (erythroid) ( 15 ) , HeLa (cervical) ( 1 , 6 , 14 , 23 , 30 , 36 , 39 , 41 ) , HeLa S3 (cervical) [PLK1 (human), knockdown, Tet-inducible PLK1 siRNA] ( 28 ) , HeLa S3 (cervical) ( 28 , 35 , 37 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 8 ) , HMLER ('stem, breast cancer') ( 8 ) , HUES-7 ('stem, embryonic') ( 38 ) , HUES-9 ('stem, embryonic') ( 29 ) , Jurkat (T lymphocyte) ( 12 , 26 , 27 , 32 , 33 ) , K562 (erythroid) ( 14 , 36 ) , Kasumi-1 (myeloid) ( 15 ) , KG-1 (myeloid) ( 15 , 20 ) , liver ( 9 ) , lung ( 10 ) , MCF-7 (breast cell) ( 4 , 16 ) , MDA-MB-231 (breast cell) ( 16 ) , MKN-45 (gastric) ( 24 , 25 ) , MV4-11 (macrophage) ( 15 , 17 ) , NCI-H1568 (pulmonary) ( 16 ) , NCI-H157 (pulmonary) ( 16 ) , NCI-H1650 (pulmonary) ( 10 ) , NCI-H1666 (pulmonary) ( 16 ) , NCI-H1975 (pulmonary) ( 10 ) , NCI-H2106 (pulmonary) ( 10 ) , NCI-H2172 (pulmonary) ( 16 ) , NCI-H520 (squamous) ( 16 ) , NCI-H647 (pulmonary) ( 16 ) , OPM-2 (plasma cell) ( 15 ) , ovary ( 7 ) , P31/FUJ (erythroid) ( 15 , 17 ) , PC9 (pulmonary) ( 16 ) , RL ('B lymphocyte, precursor') ( 15 ) , RPMI-8266 (plasma cell) ( 15 ) , SU-DHL-6 (B lymphocyte) ( 15 ) , U266 (plasma cell) ( 15 )

Upstream Regulation
Treatments:	metastatic potential ( 31 ) , nocodazole ( 35 )

References
1	Huang H, et al. (2016) Simultaneous Enrichment of Cysteine-containing Peptides and Phosphopeptides Using a Cysteine-specific Phosphonate Adaptable Tag (CysPAT) in Combination with titanium dioxide (TiO2) Chromatography. Mol Cell Proteomics 15, 3282-3296 27281782 Curated Info
2	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
3	Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610 27184836 Curated Info
4	Carrier M, et al. (2016) Phosphoproteome and Transcriptome of RA-Responsive and RA-Resistant Breast Cancer Cell Lines. PLoS One 11, e0157290 27362937 Curated Info
5	Franchin C, et al. (2015) Quantitative analysis of a phosphoproteome readily altered by the protein kinase CK2 inhibitor quinalizarin in HEK-293T cells. Biochim Biophys Acta 1854, 609-23 25278378 Curated Info
6	Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94 25159151 Curated Info
7	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
8	Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90 24782546 Curated Info
9	Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62 24275569 Curated Info
10	Rikova K, Hall B (2013) CST Curation Set: 20738, 21165, 30164, 30165, 30166; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
11	Kim JY, et al. (2013) Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. Proc Natl Acad Sci U S A 110, 12414-9 23836654 Curated Info
12	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
13	Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21 23312004 Curated Info
14	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
15	Casado P, et al. (2013) Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors. Genome Biol 14, R37 23628362 Curated Info
16	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
17	Alcolea MP, et al. (2012) Phosphoproteomic analysis of leukemia cells under basal and drug-treated conditions identifies markers of kinase pathway activation and mechanisms of resistance. Mol Cell Proteomics 11, 453-66 22547687 Curated Info
18	Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70 22496350 Curated Info
19	Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25 22424773 Curated Info
20	Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56 22115753 Curated Info
21	Mulhern D (2012) CST Curation Set: 13331; Year: 2012; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Curated Info
22	Mulhern D (2012) CST Curation Set: 13332; Year: 2012; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Curated Info
23	Grosstessner-Hain K, et al. (2011) Quantitative phospho-proteomics to investigate the polo-like kinase 1-dependent phospho-proteome. Mol Cell Proteomics 10, M111.008540 21857030 Curated Info
24	Mulhern D (2011) CST Curation Set: 12864; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: TPP Motif (TPP) (D61C3) Rabbit mAb Cat#: 5757, PTMScan(R) TPP Motif (TPP) Immunoaffinity Beads Cat#: 5758 Curated Info
25	Mulhern D (2011) CST Curation Set: 12865; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: TPP Motif (TPP) (D61C3) Rabbit mAb Cat#: 5757, PTMScan(R) TPP Motif (TPP) Immunoaffinity Beads Cat#: 5758 Curated Info
26	Mulhern D (2011) CST Curation Set: 12688; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
27	Mulhern D (2011) CST Curation Set: 12698; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
28	Santamaria A, et al. (2011) The Plk1-dependent phosphoproteome of the early mitotic spindle. Mol Cell Proteomics 10, M110.004457 20860994 Curated Info
29	Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3 21406692 Curated Info
30	Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5 21712546 Curated Info
31	Wang YT, et al. (2010) An informatics-assisted label-free quantitation strategy that depicts phosphoproteomic profiles in lung cancer cell invasion. J Proteome Res 9, 5582-97 20815410 Curated Info
32	Possemato A (2010) CST Curation Set: 10050; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
33	Possemato A (2010) CST Curation Set: 10051; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
34	Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53 20363803 Curated Info
35	Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3 20068231 Curated Info
36	Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808 19651622 Curated Info
37	Malik R, et al. (2009) Quantitative analysis of the human spindle phosphoproteome at distinct mitotic stages. J Proteome Res 8, 4553-63 19691289 Curated Info
38	Van Hoof D, et al. (2009) Phosphorylation dynamics during early differentiation of human embryonic stem cells. Cell Stem Cell 5, 214-26 19664995 Curated Info
39	Yu LR, et al. (2007) Improved titanium dioxide enrichment of phosphopeptides from HeLa cells and high confident phosphopeptide identification by cross-validation of MS/MS and MS/MS/MS spectra. J Proteome Res 6, 4150-62 17924679 Curated Info
40	Molina H, et al. (2007) Global proteomic profiling of phosphopeptides using electron transfer dissociation tandem mass spectrometry. Proc Natl Acad Sci U S A 104, 2199-204 17287340 Curated Info
41	Olsen JV, et al. (2006) Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell 127, 635-48 17081983 Curated Info